Salvage chemotherapy for ovarian cancer recurrence: Weekly cisplatin in combination with epirubicin or etoposide

Flavia Zanaboni, Giovanna Scarfone, Mauro Presti, Renato Maggi, Caterina Borello, Giorgio Bolis

Research output: Contribution to journalArticle

Abstract

From December 1986 to April 1990, 40 consecutive ovarian cancer patients who relapsed after response to cisplatin-based chemotherapy regimens were treated with seven courses of weekly cisplatin, in combination with epirubicin or etoposide. The overall response rate obtained with the intensive schedule was 60% and the complete response rate was 25%; median duration of response was 7 months and median survival time, 13.5 months. Responsive cases seem to have longer survival; a prognostic factor for response to salvage treatment and longer survival is the disease-free interval after the first-line chemotherapy. Weekly cisplatin as intensive treatment was very well tolerated and showed acceptable toxicity in both the combination protocols with epirubicin or etoposide.

Original languageEnglish
Pages (from-to)24-28
Number of pages5
JournalGynecologic Oncology
Volume43
Issue number1
DOIs
Publication statusPublished - 1991

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Fingerprint Dive into the research topics of 'Salvage chemotherapy for ovarian cancer recurrence: Weekly cisplatin in combination with epirubicin or etoposide'. Together they form a unique fingerprint.

  • Cite this